Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Short term Debt (2017 - 2025)

BeOne Medicines (BEIGF) has disclosed Short term Debt for 10 consecutive years, with $57.3 million as the latest value for Q4 2025.

  • Quarterly Short term Debt fell 93.27% to $57.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.3 million through Dec 2025, down 93.27% year-over-year, with the annual reading at $57.3 million for FY2025, 93.27% down from the prior year.
  • Short term Debt for Q4 2025 was $57.3 million at BeOne Medicines, down from $813.3 million in the prior quarter.
  • The five-year high for Short term Debt was $863.8 million in Q3 2024, with the low at $57.3 million in Q4 2025.
  • Average Short term Debt over 5 years is $552.4 million, with a median of $441.3 million recorded in 2022.
  • The sharpest move saw Short term Debt soared 3485.1% in 2021, then plummeted 93.27% in 2025.
  • Over 5 years, Short term Debt stood at $427.6 million in 2021, then grew by 3.21% to $441.3 million in 2022, then skyrocketed by 55.99% to $688.4 million in 2023, then increased by 23.7% to $851.5 million in 2024, then tumbled by 93.27% to $57.3 million in 2025.
  • According to Business Quant data, Short term Debt over the past three periods came in at $57.3 million, $813.3 million, and $808.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.